Dr. Anne-Laure Bulin Profile

Dr. Anne-Laure Bulin

at ESRF - The European Synchrotron

SPIE Involvement:

Author

Proceedings Article | 14 August 2019 Presentation

Radioluminescent nanomaterials to induce deep-tissue PDT: towards a complete description of the therapeutic contributions (Conference Presentation)

Anne-Laure Bulin, Frédéric Chaput, Mans Broekgaarden, Lucie Sancey, Jean-Luc Ravanat, Tayyaba Hasan, Hélène Elleaume

Proceedings Volume 11070, 110705F (2019) https://doi.org/10.1117/12.2525832

KEYWORDS: Photodynamic therapy, Nanomaterials, Radiotherapy, Tissue optics, Radiation effects, 3D modeling, Radio optics, X-rays, Synchrotron radiation, Tissues

Read Abstract +

Proceedings Article | 14 March 2018 Presentation

Photodynamic therapy-based combinations to overcome molecular, cellular and stromal resistance mechanisms in ovarian and pancreatic cancer (Conference Presentation)

Imran Rizvi, Shubhankar Nath, Girgis Obaid, Huang-Chiao Huang, Mans Broekgaarden, Anne-Laure Bulin, Sriram Anbil, Utkan Demirci, David Kessel, Tayyaba Hasan

Proceedings Volume 10476, 1047604 (2018) https://doi.org/10.1117/12.2290472

KEYWORDS: Photodynamic therapy, 3D modeling, Resistance, Tumor growth modeling, Pancreatic cancer, Cancer, Oncology, 3D acquisition, Ovarian cancer, Therapeutics

Read Abstract +

Proceedings Article | 19 April 2017 Presentation

PDT-based combinations in overcoming chemoresistance from stromal and heterotypic cellular communication (Conference Presentation)

Imran Rizvi, Anne-Laure Bulin, Sriram Anbil, Emma Briars, Daniela Vecchio, Jonathan Celli, Mans Broekgaarden, Tayyaba Hasan

Proceedings Volume 10047, 1004705 (2017) https://doi.org/10.1117/12.2252685

KEYWORDS: Tumors, 3D modeling, Photodynamic therapy, Cancer, Tumor growth modeling, Resistance, Ovarian cancer, Toxicity, Oncology, Image analysis

Read Abstract +

Proceedings Article | 26 April 2016 Presentation

Site-specific antibody-liposome conjugation through copper-free click chemistry: a molecular biology approach for targeted photodynamic therapy (Conference Presentation)

Girgis Obaid, Yucheng Wang, Jerrin Kuriakose, Mans Broekgaarden, Ahmed Alkhateeb, Anne-Laure Bulin, James Hui, Andrew Tsourkas, Tayyaba Hasan

Proceedings Volume 9694, 96940U (2016) https://doi.org/10.1117/12.2214253

KEYWORDS: Photodynamic therapy, Chemistry, Photosensitizer targeting, Molecular biology, Photomedicine, Target recognition, Tumors, Therapeutics, Tolerancing, Toxicity

Read Abstract +

Nanocarriers, such as liposomes, have the ability to potentiate photodynamic therapy (PDT) treatment regimens by the encapsulation of high payloads of photosensitizers and enhance their passive delivery to tumors through the enhanced permeability and retention effect. By conjugating targeting moieties to the surface of the liposomal nanoconstructs, cellular selectivity is imparted on them and PDT-based therapies can be performed with significantly higher dose tolerances, as off-target toxicity is simultaneously reduced.1 However, the maximal benefits of conventional targeted nanocarriers, including liposomes, are hindered by practical limitations including chemical instability, non-selective conjugation chemistry, poor control over ligand orientation, and loss of ligand functionality following conjugation, amongst others.2 We have developed a robust, physically and chemically stable liposomal nanoplatform containing benzoporphyrin derivative photosensitizer molecules within the phospholipid bilayer and an optimized surface density of strained cyclooctyne moieties for ‘click’ conjugation to azido-functionalized antibodies.3 The clinical chimeric anti-EGFR antibody Cetuximab is site-specifically photocrosslinked to a recombinant bioengineered that recognizes the antibody’s Fc region, containing a terminal azide.4 The copper-free click conjugation of the bioengineered Cetuximab derivative to the optimized photosensitizing liposome provides exceptional control over the antibody’s optimal orientation for cellular antigen binding. Importantly, the reaction occurs rapidly under physiological conditions, bioorthogonally (selectively in the presence of other biomolecules) and without the need for toxic copper catalysis.3 Such state-of-the-art conjugation strategies push the boundaries of targeted photodynamic therapy beyond the limitations of traditional chemical coupling techniques to produce more robust and effective targeted therapeutics with applications beyond conventional treatments.

Proceedings Article | 26 April 2016 Presentation

Designing PDT-based combinations to overcome chemoresistance in heterocellular 3D tumor models (Conference Presentation)

Imran Rizvi, Emma Briars, Anne-Laure Bulin, Sriram Anbil, Daniela Vecchio, Ahmed Alkhateeb, William Hanna, Jonathan Celli, Tayyaba Hasan

Proceedings Volume 9694, 969404 (2016) https://doi.org/10.1117/12.2213436

KEYWORDS: 3D modeling, Tumors, Resistance, Photodynamic therapy, Tumor growth modeling, Photomedicine, Cancer, Oncology, Therapeutics, Toxicity

Read Abstract +

Conference Committee Involvement (1)

17th International Photodynamic Association World Congress

28 June 2019 | Cambridge, Massachusetts, United States

Keywords/Phrases

Search In:

Publication Years